股深静脉血栓评估与清除在急性髂股深静脉血栓经皮机械血栓清除术中的结局
结果显示联合PFV-TEC组24个月髂股静脉和股深静脉通畅率分别为90%和89%,均显著高于未联合组,且血栓后综合征(PTS)发生率显著降低(11% vs. 32%)。
要点
- PMT联合PFV-TEC可提高24个月髂股静脉和股深静脉通畅率。
- PMT联合PFV-TEC显著降低24个月PTS发生率(11% vs. 32%)。
- 髂股静脉通畅和股深静脉通畅是PTS的独立保护因素。
核心结论
- PMT联合PFV-TEC改善髂股静脉和股深静脉通畅率,并降低PTS发生率。
- 推荐在急性髂股DVT的PMT治疗中实施PFV-TEC。
研究设计与样本
- 回顾性分析CODA研究(NCT06124768)2021年1月至2022年12月数据。
- 分为PMT联合PFV-TEC组43例和PMT未联合PFV-TEC组50例。
- 联合组中39例存在股深静脉血栓并成功接受PMT。
主要发现
- 联合组24个月髂股静脉通畅率为90%,显著高于未联合组(p = .033)。
- 联合组24个月股深静脉通畅率为89%,显著高于未联合组(p = .001)。
- 联合组24个月PTS发生率为11%,显著低于未联合组的32%(p = .020)。
- 多因素分析显示髂股静脉通畅(HR 0.07,95%CI 0.02-0.38;p = .002)和股深静脉通畅(HR 0.07,95%CI 0.01-0.61;p = .017)是PTS的独立保护因素。
临床怎么用
- 在急性髂股DVT行PMT治疗时,应评估并清除股深静脉血栓以改善通畅率并降低PTS风险。
局限性
- 本研究为回顾性分析,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to investigate the outcomes of profunda femoris vein thrombosis evaluation and clearance (PFV-TEC) by percutaneous mechanical thrombectomy (PMT) for acute iliofemoral deep vein thrombosis (DVT). METHODS: This study retrospectively analysed data from the CODA study (NCT06124768) from January 2021 to December 2022. Consecutive patients with acute iliofemoral DVT treated by PMT were included. Patients were categorised into two treatment groups: PMT with PFV-TEC and PMT without PFV-TEC. The primary efficacy outcome was the 24 month incidence of post-thrombotic syndrome (PTS). RESULTS: Ninety-three patients were included: 43 patients underwent PMT with PFV-TEC and 50 patients without PFV-TEC. In the PMT with PFV-TEC group, 39 patients had profunda femoris vein (PFV) thrombosis and successfully underwent PMT. The 24 month iliofemoral vein and PFV patency rates were 90% and 89% in the PMT with PFV-TEC group, which were statistically significantly higher than those in the PMT without PFV-TEC group (p = .033 and p = .001, respectively). The 24 month incidence of PTS was statistically significantly lower in the PMT with PFV-TEC group than in the PMT without PFV-TEC group (11% vs. 32%; p = .020). Multivariable analysis identified iliofemoral vein patency (hazard ratio [HR] 0.07, 95% confidence interval [CI] 0.02 - 0.38; p = .002) and PFV patency (HR 0.07, 95% CI 0.01 - 0.61; p = .017) as independent protective factors against PTS. CONCLUSION: PMT with PFV-TEC improved iliofemoral and PFV patency and decreased the incidence of PTS. PFV-TEC is recommended in PMT treatment for acute iliofemoral DVT.
引用
- Ni Q, Liu Y, Chen J, et al. Outcomes of Profunda Femoris Vein Thrombosis Evaluation and Clearance by Percutaneous Mechanical Thrombectomy for Acute Iliofemoral Deep Vein Thrombosis. Eur J Vasc Endovasc Surg. 2025. PMID: 41192542. doi:10.1016/j.ejvs.2025.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。